Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.2060
-0.0140 (-6.36%)
At close: Mar 28, 2025, 4:00 PM
0.2029
-0.0031 (-1.52%)
After-hours: Mar 28, 2025, 4:39 PM EDT
Adaptimmune Therapeutics Stock Forecast
ADAP's stock price has decreased by -86.97% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Adaptimmune Therapeutics stock have an average target of 1.93, with a low estimate of 1.40 and a high estimate of 3.50. The average target predicts an increase of 836.89% from the current stock price of 0.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adaptimmune Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $3 → $1.75 | Strong Buy | Maintains | $3 → $1.75 | +749.51% | Mar 26, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $2 → $1.5 | Hold | Maintains | $2 → $1.5 | +628.16% | Mar 21, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $3.15 → $1.4 | Buy | Maintains | $3.15 → $1.4 | +579.61% | Mar 21, 2025 |
| Mizuho | Mizuho | Buy Maintains $3 → $1.5 | Buy | Maintains | $3 → $1.5 | +628.16% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.5 | Strong Buy | Reiterates | $3.5 | +1,599.03% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
40.12M
from 178.03M
Decreased by -77.46%
Revenue Next Year
62.94M
from 40.12M
Increased by 56.87%
EPS This Year
-0.40
from -0.30
EPS Next Year
-0.36
from -0.40
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.8M | 80.8M | 235.4M | ||
| Avg | 40.1M | 62.9M | 145.8M | ||
| Low | 15.5M | 43.7M | 77.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -67.0% | 101.3% | 274.0% | ||
| Avg | -77.5% | 56.9% | 131.7% | ||
| Low | -91.3% | 8.9% | 23.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.11 | -0.06 | -0.36 |
| Avg | -0.40 | -0.36 | -0.35 |
| Low | -0.54 | -0.49 | -0.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.